Thyroid Hormone-Induced Expression of the Hepatic Scaffold Proteins Sestrin2, β-Klotho, and FRS2α in Relation to FGF21-AMPK Signaling

Abstract

Thyroid hormone (3,3′,5-triiodothyronine, T₃) accelerates energy metabolism in the liver through mechanisms involving upregulation of AMP-activated protein kinase (AMPK). This study aims to assess the influence of T₃ on the expression of the scaffold proteins β-Klotho, fibroblast growth factor receptor substrate 2α (FRS2α), and Sestrin2 in relation to FGF21-AMPK signaling. Male Sprague-Dawley rats were given 0.1 mg T₃/kg or hormone vehicle (controls) and studies were done 24 h after treatment. These include measurements of the mRNA expression (qPCR) of hepatic β-Klotho, FGF21, FGF21 receptor-1 (FGFR1), extracellular-signal-regulated kinase 1/2 (ERK1/2), FRS2α, ribosomal S6 kinase-1 (RSK1), liver kinase B1 (LKB1), AMPK, and Sestrin2. Also, protein levels of FGF21, FGFR1 (ELISA), and ERK1/2 (Western blot) were measured. T₃ elicited a calorigenic response with higher hepatic mRNA expression of β-Klotho, FRS2α, and FGF21, increased serum FGF21, without changes in liver FGFR1 mRNA and its plasma levels. In addition, T₃ enhanced ERK1/2 phosphorylation and the mRNA expression of ERK1/2, RSK1, LKB1, AMPK, and Sestrin2. T₃ administration enhances liver FGF21-AMPK signaling involving upregulation of the scaffold proteins β-Klotho, FRS2α, and Sestrin2. β-Klotho and FRS2 induction favours the operation of the FGF21-FGFR1-β-Klotho complex as evidenced by the enhancement in ERK1/2 phosphorylation, whereas that of Sestrin2 recruits LKB1 to achieved AMPK activation, thus supporting a higher energy expenditure condition that may be desirable in some metabolic disorders

Key words

thyroid hormone - liver - β-Klotho - Sestrin2 - FGF21-AMPK signaling

• References

• 1 Langeberg LK, Scott JD. Signalling scaffolds and local organization of cellular behaviour. Nat Rev Mol Cell Biol 2015; 16: 232-244
• 2 Vondriska TM, Pass JM, Ping P. Scaffold proteins and assembly of multiprotein signaling complexes. J Mol Cell Cardiol 2004; 37: 391-397
• 3 Lemmon MM, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134
• 4 Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol 2016; 78: 223-241
• 5 Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014; 94: 355-382
• 6 Hardie DG. AMP-activated protein kinase: An energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25: 1895-1908
• 7 Vargas R, Ortega Y, Bozo V. et al. Thyroid hormone activates rat liver adenosine 5’-monophosphate-activated protein kinase: Relation of CaMKKβ, TAK1, and LKB1 expression and energy status. J Biol Regul Homeost Agents 2013; 27: 989-999
• 8 Videla LA, Fernández V, Cornejo P. et al. T₃-induced liver AMP-activated protein kinase signaling: Redox dependency and upregulation of downstream targets. World J Gastroenterol 2014; 20: 17416-17425
• 9 Videla LA, Fernández V, Cornejo P. et al. Thyroid hormone in the frontier of cell protection, survival and functional recovery. Expert Rev Mol Med 2015; 17: 17:e10
• 10 Chau MD, Gao J, Yang Q. et al. Fibroblast growth factor 21 regulates energy metabolism by activating AMPK-SIRT1-PGC-1α pathway. Proc Nat Acad Sci USA 2010; 107: 12553-12558
• 11 Lundassen T, Hunt MC, Nilsson LM. et al. PPARα is a key regulator of FGF21. Biochim Biophys Res Commun 2007; 360: 437-440
• 12 Adams AC, Astapova I, Fisher FM. et al. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARα-dependent manner. J Biol Chem 2010; 285: 14078-14082
• 13 Videla LA, Fernández V, Vargas R. et al. Upregulation of rat liver PPARα-FGF21 signaling by a docosahexaenoic acid and thyroid hormone combined protocol. BioFactors 2016; 42: 638-646
• 14 Kharitonenko A, Dunbar JD, Bina HA. et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J Cell Physiol 2008; 215: 1-7
• 15 Morrison A, Chen L, Wang J. et al. Sestrin2 promotes LKB1-mediated AMPK activation in the ischemic heart. FASEB J 2015; 29: 408-417
• 16 Ogawa Y, Kurosu H, Yamamoto M. et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 2007; 104: 7432-7437
• 17 Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci 2008; 99: 13119-13125
• 18 Ding X, Boney-Montoya J, Owen BM. et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 2012; 16: 387-393
• 19 Lara R, Seckl MJ, Pardo OE. The p90 family members: Common functions and isoform specificity. Cancer Res 2013; 73: 5301-5308
• 20 Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75: 137-163
• 21 Li L, Xiao L, Hou Y. et al. Zhao, Sestrin2 silencing exacerbates cerebral ischemia/reperfusión injury by decreasing mitochondrial biogenesis through the AMPK/PGC-1α pathway in rats. Sci Rep 2016; 6: 30272
• 22 Shin BY, Jin SH, Cho IJ. et al. Nrf2-ARE pathway regulates induction of sestrin-2 expression. Free Radic Biol Med 2012; 53: 834-841
• 23 Romanque P, Cornejo P, Valdés S. et al. Thyroid hormone administration induces rat liver Nrf2 activation: Suppression by N-acetylcysteine pretreatment. Thyroid 2011; 21: 655-662
• 24 Park HW, Park H, Ro SH. et al. Hepatoprotective role of Sestrin2 against chronic ER stress. Nature Commun 2014; 5: 4233
• 25 Ro SH, Semple I, Ho A. et al. Sestrin2, a regulator of thermogenesis and mitohormesis in brown adipose tissue. Front Endocrinol 2015; 6: 114
• 26 Kim KM, Yang JH, Shin SM. et al. Sestrin2: A promising therapeutic target for liver diseases. Biol Pharm Bull 2015; 38: 966-970
• 27 Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders. Front Endocrinol 2015; 6: 168
• 28 Martínez-Sánchez N, Moreno-Navarrete JM, Contreras C. et al. Thyroid hormones induce browning of white fat. J Endocrinol 2017; 232: 351-362
• 29 Coppola M, Cioffi F, Moreno M. et al. 3,5-Diiodo-L-thyronine: A possible pharmacological agent?. Curr Drug Deliv 2016; 13: 330-338